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A B S T R A C T
Aim: The size of regional, tumor draining lymph nodes without metastasis (LNneg) found in rectal cancer re-
section specimens varies and seems to be related to patient survival. Yet, the histopathological features influ-
encing LNneg size in rectal cancer have not been studied in detail. Our pilot study focused on investigating the
relationship between lymph node (LN) size and LNneg microarchitecture in rectal cancer (RC) resection spe-
cimens.
Method: In this retrospective cohort study, resection specimens from 146 RC patients, treated with either surgery
alone (n = 29) or neoadjuvant therapy followed by resection (n = 117), were included in the study. Histology of
LNnegs was reviewed to establish number of lymphoid follicles and presence of intranodal fat. Longest long axis
and area of each LN were measured digitally.
Results: 1830 LNnegs were measured. The microarchitecture was analyzed in a subset of 680 LNnegs. 153 (22.5
%) LNnegs contained intranodal fat. After neoadjuvant treatment, presence of intranodal fat was related to
smaller LNneg area (median (range) area of LNneg without intranodal fat: 4.51 mm2 (0.15-46.89 mm2), with
intranodal fat: 3.46 mm2 (0.12-27.22 mm2), p = 0.048). A higher number of lymphoid follicles was related to a
larger LNneg area in both patient groups (p<0.001).
Conclusion: Our pilot data suggest that in rectal cancer the presence of large regional LNnegs may reflect in-
creased immune activation due to tumor related antigens. Further studies are warranted to investigate whether
histologically visible microarchitectural features of LNnegs such as lymphoid follicles translate to particular
features in radiological images and hence could potentially help to identify LNneg with more certainty at the
time of pre-treatment disease staging.
1. Introduction
The number of lymph nodes (LNs) with metastasis (LNpos) is an
important prognostic factor for colorectal cancer patients and de-
termines the N status within the TNM staging [1]. A number of studies
proposed that the absolute total number of LNs retrieved from the re-
section specimen and/or LN ratio (LNpos/LNs) are related to prognosis
in rectal cancer (RC) patients [2–4].
TNM staging is currently the main clinical tool to determine a pa-
tient’s prognosis and treatment plan. The N status refers to the number
of regional LNpos and is one of the most important prognostic markers
with therapeutic consequences [4]. LNs without metastasis (LNnegs)
are increasingly being studied in patients with colorectal cancer
[2,5–11] and it has been suggested that larger LNnegs in patients with
pT1 or pT2 colon cancer might be related to a favorable outcome [12].
Murphy et al. found a better five-year survival in Dukes stage 3 RC
patients with a higher number or a larger size of LNnegs [3]. A high LN
yield in RC resection specimens has been related to a better prognosis
[13]. It has also been shown that the longer the LN long axis, the higher
the LN yield in colon cancer resection specimens [14] and that the total
number of resected LNs is an independent prognostic factor [2].
Variations in regional LN size have been demonstrated in RC pa-
tients for LNpos and LNneg [5,6,10]. There is evidence to suggest that
the LN microarchitecture changes depending on the status of the im-
mune system of the host [15]. LN size differences have been related to
prognosis and immune activation in previous studies [16,5,12]. There is
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also evidence suggesting LN size may be related to the extent of in-
tranodal connective tissue present without evidence of prior infection
or cancer [17,18], and smaller LNs may reflect a reduced function of the
immune system in the elderly [19]. Increased LN size has been related
to reactive hyperplasia within the LN, e.g. increased number of immune
cells in LNs draining infections or neoplasm and thus were related to the
immunological response by the patient [20,16]. In RC patients, large LN
size was found to be independent of tumor size [5]. Other morpholo-
gical changes, like presence of intranodal fat have been previously
described in LNs and may influence LN size [17]. Chemoradiotherapy
(CRT) had no effect on LNneg size in RC according to Kim et al. [21],
whereas Heijen et al., although not distinguishing between size of
LNpos and LNneg, reported a decrease in LN size after CRT [22].
However, the microarchitecture of LNnegs retrieved from RC resection
specimens and its relationship with LNneg size has not been studied in
detail until now.
We hypothesized that LNneg size variation in RC patients is related
to the variation in the number of primary and secondary lymphoid
follicles and the presence of intranodal fat.
In this pilot study, we aimed to investigate the relationship between
LNneg microarchitecture (number of primary and secondary lymphoid
follicles, presence of intranodal fat), LNneg size (largest diameter),
LNneg area (mm2) and clinicopathological characteristics (age, sex, LN
location, depth of invasion (pT) and lymph node status (pN)) in 146 RC
patients treated by neoadjuvant therapy and surgery or surgery alone.
2. Material and method
This retrospective cohort study included 1951 lymph nodes (LNs),
both with and without metastasis, from 146 consecutive patients with
rectal cancer (RC) with (y)pT0 to (y)pT4 disease who were treated with
neoadjuvant therapy followed by surgery (n = 89) or surgery alone at
the Department of Surgery, Maastricht University Medical Center+
(MUMC+), Maastricht, NL between 2008 and 2015 (Fig. 1). Patients
with recurrent rectal cancer were excluded. Clinicopathological data
was retrieved retrospectively from a departmental database, surgery
reports and pathology reports. The study was approved by the local
regulatory body (METC 2018−0672).
2.1. Data collection
All diagnostic Haematoxylin/Eosin (H&E) stained slides from the RC
resection specimens were retrieved from the local pathology archive
and slides containing LNs were scanned with a HP flatbed scanner
(N6310 HP Scanjet) set at 600ppi resolution. If multiple slides with LNs
of the resection specimen were missing, the patient was excluded from
the study. For microarchitecture analysis, scans were imported into
image analysis software (Medical Image Manager (MIM), HeteroGenius
Ltd. Leeds, UK). The pathology was done according to best practice and
the pathology reports were used to identify LNs containing metastasis.
The largest section of each LNnegs and LNpos was manually outlined
using the curve tool at 10x magnification. The LN capsule was included
in the LN outline, fatty tissue and vascular structures outside of the LN
capsule were excluded (Fig. 2). The MIM software calculated the area
and longest axis after appropriate calibration.
In a randomly selected subset of 51 RC patients, with similar sex and
treatment compared to the full dataset, LNnegs were reviewed using a
conventional light microscope with a 2.5x objective to count primary
lymphoid follicles, secondary lymphoid follicles and establish whether
fat was present inside the LN. The slide review and measurements were
done blinded to clinicopathological parameter. A lymphoid follicle was
classified as primary follicle if no germinal center was visible and as a
secondary follicle if a germinal center was clearly visible within the
follicle (Fig. 3) [15]. The number of primary and secondary lymphoid
follicles was initially counted separately in 4 categories: 0 lymphoid
follicles, 1–3 lymphoid follicles, 4–9 lymphoid follicles and ≥10
lymphoid follicles. Subsequently, the primary and secondary lymphoid
follicle categories were combined for a final lymphoid follicle score as
follows: if the sum of the primary lymphoid follicle score and the sec-
ondary lymphoid follicle score was 0, the final lymphoid follicle score
was 1; if the sum was 1, the final lymphoid follicle score was 2; if the
sum was 2, the final lymphoid follicle score was 3; if the sum was 3, the
final lymphoid follicle score was 4. If the sum was>3, the final lym-
phoid follicle score was 5. Intranodal fat was categorized as being
present if one or more adipocytes were visible within the H&E stained
LNneg. Adipocytes outside the capsule or LN tissue were not con-
sidered.
Five percent of the examined LNnegs were randomly selected for re-
evaluation by the primary observer and a second observer to assess
intra- and interobserver agreement of the measurement.
Information on the location of individual LNnegs within the cir-
cumferential mesorectal fat was included in the analyses if available
from patient records according to the Beets-Tan protocol [23]. For re-
section specimens which were dissected using the Beets-Tan protocol,
the rectum including surrounding fat was sliced perpendicular to its
longitudinal axis and the pathologist recorded the location of the lymph
node in the mesorectal fat using a clock face with 12 o’clock being
located anterior.
Findings from the randomly selected 51 patients were compared
between those who had neoadjuvant treatment followed by surgery and
those treated with surgery alone (S).
2.2. Statistical analysis
Statistical analysis was performed using SPSS statistics software
(version 23, IBM, Hampshire, England). Kruskal-Wallis test and Mann
Whitney-U test were used to investigate the relationship between LN
long axis and the patients’ sex, (y)pT, (y)pN and LN location in the
mesorectal fat. Kruskal-Wallis test and Mann Whitney-U test were also
used to analyze the relationship between LNneg area, lymphoid follicle
score and presence of intranodal fat. Results are reported either as
absolute values or median (range). Two-sided p-values less than 0.05
were considered significant.
3. Results
The current study included 97 (66 %) males and 49 females with a
median age of 68 years (range: 42–86 years). 118 (80.8 %) patients had
neoadjuvant treatment before surgical resection. Of the patients with
neoadjuvant treatment, 116 (98.3 %) patients received radiotherapy,
40 (33.9 %) patients received 5 × 5 Gy and 76 (64.4 %) patients re-
ceived 5-flourouracil (5-FU) long course chemoradiotherapy. 66 (55.9
%) patients were given adjuvant treatment with capecitabine, 16 (13.6
%) patients were treated with capecitabine and oxaliplatin and 24 (20.3
%) patients with only radiotherapy. Details of adjuvant chemotherapy
were unknown for 14 (11.7 %) patients. 106 (72.7 %) patients under-
went a lower anterior resection with total mesorectal excision, 17 (11.6
%) patients had an abdominoperineal rectum extirpation and the re-
maining patients underwent a Hartmann procedure (n = 8, 5.5 %) or
pelvic exenteration (n = 4, 2.7 %). Type of surgery was unknown for 11
(7.5 %) patients. In total, 1951 LNs were retrieved from the 146 re-
section specimens (Table 1). A median (range) of 12 LNs (3–38 LNs)
and a median (range) of 11 LNnegs (3–37 LNnegs) were retrieved per
specimen. 121 (6.2 %) LNs contained tumor metastasis and 1820 (93.8
%) were negative (Table 1). The long axis of LNnegs was significantly
shorter than that of LNpos (median long axis (range) LNneg 2.8 mm
(0.42–27.78 mm) vs. LNpos 5.3 mm (1.53–22.96 mm), p< 0.001).
The microarchitecture was assessed in detail in LNnegs from 51 RC
patients (Fig. 3). The microarchitecture of LNpos was not investigated
due to the overall relatively low number of LNpos (n = 60) available in
this subcohort. From the 51 patients, 31 (60.7 %) were males, the
median (range) age was 69 years (42–86 years), and 34 (66.7 %) had
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neoadjuvant treatment before surgical resection. In this subcohort, 14
(27.5 %) patients received neoadjuvant treatment with 5 × 5 Gy
radiotherapy, 4 (7.8 %) patients with 5 × 5 Gy radiotherapy combined
with chemotherapy and 16 (31.4 %) patients with 5-FU long course
chemoradiotherapy. A total of 680 LNnegs was retrieved from these 51
patients with a median (range) of 11 (2–37) LNnegs per patient. The
median (range) area of this subset of LNnegs was 4.40mm2 (0.12-51.43
mm2). The LNneg area was smaller after neoadjuvant treatment
(median (range) after neoadjuvant treatment 4.24 mm2 (0.12-46.89
mm2) versus 4.67 mm2 (0.39-51.43 mm2) without neoadjuvant treat-
ment (p = 0.026)).
3.1. Relationship of lymph node long axis length and patient characteristics
The LNneg long axis was longer in males compared to females in the
cohort of 148 patients (Table 2). The length of the LNneg long axis was
related to the depth of invasion ((y)pT) and lymph node status ((y)pN).
The LNneg long axis of patients with (y)pT0 RC was shorter than in
patients with (y)pT4 RC (median (range) LNneg long axis (y)pT0 (n =
92): 2.24 mm (0.79–9.25 mm) vs. (y)pT4 (n = 258): 3.38 mm
(0.72–9.98 mm), p< 0.001). Median (range) of the LNneg long axis in
patients with (y)pN0 (number of LN n = 1139) was 2.73 mm
(0.42–15.49 mm); (y)pN1 (n = 520): 3.04 mm (0.43–27.78 mm) and
(y)pN2 (n = 171) 3.12 mm (0.56–11.23 mm), respectively, p< 0.001).
There was no relationship between (y)pT category and length of the
Fig. 1. Consort diagram showing the inclusion process of the lymph nodes (LNs). Selection 1 was used for the large cohort analysis. Selection 2 was used for the
subcohort analysis of histological characteristics. NAT = neoadjuvant treatment, LN = lymph node, LNneg = negative lymph node, LNpos = positive lymph node.
Fig. 2. Examples of manual outlining of lymph nodes using MIM image analysis software after scanning of Haematoxylin/Eosin stained sections on a flatbed scanner
at 600 ppi.
J. Ruisch, et al. Pathology - Research and Practice 216 (2020) 153106
3
LNpos long axis.
For 775 (79.2 %) LNs of the subcohort, the location within the
mesorectal fat was known using a clock face with 12 o’clock being lo-
cated anteriorly according to the Beets-Tan protocol [23]. There was no
significant relationship between the length of the long axis of LNnegs (n
= 727) and location within the mesorectal fat (median (range) LNneg
largest diameter of 3.2 mm (0.50–9.4 mm) posterior and 3.7 mm
(0.50–5.2 mm) anterior; p = 0.686).
3.2. Negative lymph node microarchitecture and relationship to lymph node
size
LNneg microarchitecture was assessed based on number of
lymphoid follicles and presence of intranodal fat in 51 patients. LNneg
size was related to the total follicle count (p< 0.001) irrespective
whether patients had neoadjuvant treatment (n = 434 LNnegs) or not
(n = 246 LNnegs). In neoadjuvant treatment patients, 161 LNnegs with
Fig. 3. Representative images of lymphoid follicles and intranodal lipomatosis. a. shows intranodal fat (arrow). b. shows lipomatosis around the LN and absence of
LN capsule (arrow). c. shows a LN with multiple primary lymphoid follicles (for example see square) and secondary lymphoid follicles (see ellipse). d. shows a
secondary lymphoid follicle at higher magnification (arrow).
Table 1
Relationship between number of lymph nodes and clinicopathological variables.
Lymph nodes full patient cohort (n = 1951) LNnegs patient subcohorta (n = 680)
After neoadjuvant treatment (n = 434) No neoadjuvant treatment (n = 246)
LNpos (n) % LNneg (n) % LNneg (n) % LNneg (n) %
121 100 1830 100 434 100 246 100
(y)pT category [1]
T0 1 0.8 92 5.0 28 6.5 21 8.5
T1 2 1.7 79 4.3 45 10.6 29 11.8
T2 24 19.8 284 15.5 98 22.6 106 43.1
T3 85 70.3 1117 61.0 253 58.3 53 21.5
T4 9 7.4 258 14.1 10 2.3 37 15.0
(y)pN category
N0 0 – 1139 62.2 207 47.7 162 65.9
N1 52 43.0 520 28.4 202 46.5 63 25.6
N2 69 57.0 171 9.3 26 6.0 21 8.5
Sex
Male 79 65.3 1166 63.7 220 50.7 113 45.9
Female 42 34.7 664 36.3 214 49.3 133 54.1
Age
≤64 59 48.8 665 36.3 164 37.8 63 25.6
65−79 53 43.8 974 53.2 176 40.6 175 71.1
80+ 9 7.4 191 10.4 95 21.9 8 3.3
[1] Gospodarowicz MK, Brierley, J. D., & Wittekind, C. TNM classification of malignant tumours. John Wiley & Sons. (2017) TNM classification of malignant
tumours. John Wiley & Sons.
a The subcohort consists of 51 randomly slected patients from whom the LN microarchitecture was assessed.
Table 2
Relationship between largest diameter of positive or negative lymph nodes and
sex.
Median largest long axis (range) in mm
Males (n = 97) Females (n = 49) p-value
LNpos 5.33 (1.88–22.96) 5.12 (1.53–16.56) 0.327
LNneg 2.92 (0.43–27.78) 2.61 (0.42–9.39) < 0.001
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a combined follicle score 1, e.g. no primary or secondary follicles, had
the smallest LN area (median (range) 2.32 mm2 (0.12 – 46.89 mm2)),
the 25 LNnegs with follicle score 5, e.g. at least 10 follicles (primary and
secondary combined), had the largest LN area (median (range) 9.73
mm2 (3.24 – 27.22 mm2)) (Table 3). Similarly, in surgery alone treated
patients, the 32 LNnegs with a combined follicle score 1 had the
smallest LN area (median (range) 2.15 mm2 ((0.39 – 23.98 mm2), and
the 58 LNnegs with combined follicle score 5 had the largest LN area
(median (range) 9.00 mm2 (2.35 – 50.91 mm2) (Table 3).
Patients without neoadjuvant treatment (n = 17) had more often
LNnegs with more lymphoid follicles. In patients without neoadjuvant
treatment, 23.6 % of all LNnegs had a combined follicle score 5 vs. 5.8
% of all LNnegs with a combined follicle score 5 in patients with
neoadjuvant treatment (Table 3). The intra- and interobserver con-
cordance in classifying follicles as primary or secondary and counting
the number of follicles was 72.0 % and 66.3 % for primary lymphoid
follicles and 75.0 % and 58.8 % for secondary lymphoid follicles, re-
spectively. Most differences were found between grading ‘0′ primary or
secondary lymphoid follicles and 1–3 primary or secondary lymphoid
follicles.
In LNnegs after neoadjuvant treatment (n = 434), a relationship
between LNneg area and presence of intranodal fat was seen (p =
0.048). LNneg area seemed to decrease when intranodal fat was present
(median (range) LNneg area of LNs without intranodal fat (n = 333):
4.51mm2 (0.15-46.89 mm2) versus 3.46 mm2 (0.12-46.89 mm2) of LNs
with intranodal fat (n = 101)), p = 0.048. In patients without
neoadjuvant treatment (n = 246) there was a similar trend (median
(range) LNneg area of LNs without intranodal fat (n = 194); 4.96 mm2
(0.39-51.43 mm2) versus 3.73 mm2 (0.44-23.11 mm2) of LNs with in-
tranodal fat (n = 52)), p = 0.163. The intra- and interobserver con-
cordance in determining the presence or absence of intranodal fat was
93.0 % and 83.0 %, respectively. The frequency of intranodal fat pre-
sence was comparable between patients irrespective of treatment (78.9
% without intranodal fat and 76.7 % without intranodal fat respec-
tively).
4. Discussion
This retrospective single-center pilot study explored the relationship
between lymph node (LN) area and LN microarchitecture (number of
lymphoid follicles, presence of intranodal fat) in LNs without metastasis
(LNnegs) in resection specimens from rectal cancer (RC) patients. The
LN diameters in the current study were consistent with those reported
previously [6], as was the location of LNs within the mesorectal fat [6]
and the fact that there were fewer LNs retrieved from the specimen
after neoadjuvant treatment [7,8]. Our study suggests a relationship
between sex, LNneg largest diameter and total number of resected
LNnegs. According to our findings, LNnegs are smaller in females with
RC than in males. A recent study suggested that females with colon
cancer are diagnosed at a later stage [24]. If this is also the case for
females with rectal cancer, then one could speculate that the smaller
LNnegs in females might be a reflection of an ‘exhausted’ immune
system despite the suggestion from the literature, that females have a
generally stronger immune response [25].
The number of LNnegs with intranodal fat was similar irrespective
of treatment suggesting that neoadjuvant treatment has no influence of
intranodal fat. However, LNneg largest diameter was smaller after
neoadjuvant treatment in our study confirming a previous report [26].
Interestingly, we only saw a relationship between LNneg area and
presence of intranodal fat in RC patients who were treated with
neoadjuvant therapy. It has been previously suggested that the presence
of intranodal fat could be a sign of LN atrophy after therapy [27]. Al-
ternatively, work by Huber et al. suggested that intranodal fat may have
a role as energy resource for immune cell metabolism, activation and
differentiation [28,29]. Thus, one could speculate that LNnegs without
intranodal fat might be larger due to previous intensive lymphoid cell
proliferation or differentiation which utilised all the available in-
tranodal fat.
A relation between higher number of lymphoid follicles and in-
creased LNneg area was found in the current study. This relationship
between area and number of follicles supports our hypothesis and that
of other investigators [18] that increased area of LNnegs is a surrogate
of a more activated immune system in the regional, tumor draining LNs.
Matsuno et al. reported that antigens of the tumor can lead to the ac-
tivation of an immune response via follicular hyperplasia, proliferation
of lymphocytes or sinus histiocytosis in pancreatic cancer [30]. As
follicular hyperplasia was related to larger LNneg area in our study, the
area of a LN may reflect the extent of immune activation. Kolotova et al.
suggested that treatment of RC patients with a combination of radio-
therapy and chemotherapy results in stimulation of lymph nodes by
tumor antigens leading to lymph nodes with lymphoid follicles that
almost all contain activated germinal centers [10]. Architectural
changes other than follicular hyperplasia or intranodal fat which may
potentially influence the area of LNnegs besides were not observed in
the current study. Previous studies showed fibrosis in LNs after CRT
[31,32], a parameter which was not apparent and hence not considered
in the current study.
The current study has some limitations. It is a retrospective ob-
servational pilot study in rectal cancer patients from a single center
which could have led to selection bias. As this is a hypothesis gen-
erating study, we consider the effect of this bias as minimal. As ex-
pected in rectal cancer patients, 80 % of study patients underwent
neoadjuvant treatment, so any results from comparing LNs from pa-
tients with and without neoadjuvant treatment need to be interpreted
with caution. The overall number of patients with lymph node metas-
tases included in the current study was very small and made subgroup
analysis by disease stage unfeasible. The architecture of LNpos was not
examined as we hypothesized this would reflect a different immune
status due to direct contact between immune cells and tumor cells.
Unfortunately, survival data and patient outcome was not yet mature
enough to be included in the analysis. Future prospective studies need
to include a protocol for surgeons and pathologists to facilitate
Table 3
Relationship between negative lymph node microarchitecture and neoadjuvant treatment in the subcohort of 51 rectal cancer patients.
Lymph nodes after neoadjuvant treatment (n = 434) Lymph nodes without neoadjuvant treatment (n = 246)
LNneg (n) % median area (mm2) range (mm2) p-value LNneg (n) % median area (mm2) range (mm2) p-value
Intranodal fat
With intranodal fat 101 23.3 3.46 0.12 - 27.22 0.05 52 21.1 3.73 0.44 - 23.11 0.16
Without intranodal fat 333 76.7 4.51 0.15 - 46.89 194 78.9 4.96 0.39 - 51.43
Combined lymphoid follicle score
Group 1 161 37.0 2.32 0.12 - 46.89 < 0.001 32 13.0 2.15 0.39 - 23.98 <0.001
Group 2 126 29.0 3.75 0.40 - 29.69 54 22.0 2.28 0.45 - 10.34
Group 3 72 16.6 5.82 0.79 - 20.10 52 21.1 4.04 1.46 - 32.07
Group 4 50 11.5 7.50 1.24 - 34.27 50 20.3 6.96 1.61 - 51.43
Group 5 25 5.7 9.73 3.24 - 27.22 58 23.6 9.00 2.35 - 50.91
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standardized LN collection from the specimen as well as standardized
preparation of lymph nodes for histological assessment.
In summary, our pilot study suggests that in rectal cancer patients
the area of LNnegs is related to the presence of follicular hyperplasia as
well as the presence of intranodal fat. As large LNnegs seemed to have
larger number of lymphoid follicles, we hypothesize that measuring
LNneg area could be of potential clinical value as surrogate for the
immunogenicity of the primary tumor and/or successful activation of a
host’s immune response to tumor antigens. Future studies are war-
ranted to a) investigate underlying biological mechanisms and b) to
investigate whether histologically visible microarchitectural features of
LNnegs can be related to particular radiological findings and hence
potentially help to improve LN assessment at the time of diagnosis as
well as be useful to determine patient’s treatment. To assess the po-
tential clinical importance of our findings, a study cohort with longer
follow up time would be valuable. Larger prospective multidisciplinary
studies need to be performed potentially using image analysis tools to
increase inter/intra observer accuracy and to allow studying large
number of LNs including positive LNs.
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